Literature DB >> 9231157

Interphase ribosomal RNA cistron silver staining in refractory anaemias with and without excess blasts.

N N Mamaev1, G N Salogub, I B Nefedova.   

Abstract

AIM: To evaluate the haemopoietic function of bone marrow blood forming cells in human myelodysplastic syndromes (MDS) by silver staining of nucleolar organiser regions (AgNORs).
METHODS: Nucleoli were investigated in bone marrow blast cells and in erythroid, granulocytic, and megakaryocytic cells from 12 haematologically healthy subjects, and from 26 patients with MDS, including 14 with refractory anaemia (RA), nine with RA with excess blasts (RAEB), and three with RAEB in transformation (RAEB-t). The investigation was performed before treatment using a one step silver staining method. In each case 50 to 100 blasts, promyelocytes, myelocytes, immature (pronormoblastic and basophilic normoblastic) and mature (polychromatic normoblastic) erythroid elements, and megakaryocytes were evaluated for the mean numbers of nucleoli and AgNORs per nucleus. Student's t test was used to compare the patient and control groups. Other statistical analyses were carried out by the computer assisted "HEMA" system.
RESULTS: Compared with controls, the number of AgNORs in blasts, promyelocytes, immature erythroid elements, and megakaryocytes was decreased, whereas in myelocytes and polychromatic normoblasts it was similar. There was also a difference in the AgNOR scores in blood forming cells from patients with RAEB/ RAEB-t v RA.
CONCLUSIONS: The loss of AgNOR sites in cellular series in MDS may result from the decrease of their proliferative potential with disease progression, intrinsic defects in maturation, and extensive apoptosis.

Entities:  

Mesh:

Year:  1997        PMID: 9231157      PMCID: PMC379590          DOI: 10.1136/mp.50.2.92

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  14 in total

Review 1.  Nucleolar organizer region activity in human chromosomes and interphase nuclei of normal, leukemic, and tumor cells as evaluated by silver staining.

Authors:  N N Mamaev; S E Mamaeva
Journal:  Int Rev Cytol       Date:  1990

2.  The activity of nucleolar organizer regions of human bone marrow cells studied with silver staining. I. Chronic myelocytic leukemia.

Authors:  N Mamaev; S Mamaeva; I Liburkina; T Kozlova; N Medvedeva; G Makarkina
Journal:  Cancer Genet Cytogenet       Date:  1985-04-15

3.  Ferrokinetic abnormalities and their significance in patients with sideroblastic anaemia.

Authors:  A K Singh; N K Shinton; J D Williams
Journal:  Br J Haematol       Date:  1970-01       Impact factor: 6.998

4.  Controlled silver-staining of nucleolus organizer regions with a protective colloidal developer: a 1-step method.

Authors:  W M Howell; D A Black
Journal:  Experientia       Date:  1980-08-15

5.  Megakaryocytic ploidy in myelodysplastic syndromes.

Authors:  Y Kobayashi; M Ozawa; N Maruo; M Kondo
Journal:  Leuk Lymphoma       Date:  1993-01

6.  Interphase ribosomal RNA cistron staining in chronic myeloid leukaemia.

Authors:  N N Mamaev; G N Salogub; A V Koloskov
Journal:  Clin Mol Pathol       Date:  1995-10

7.  [Morpho-functional characteristics of normal and pathological human megakaryocytes studied by selective silver staining of cell nucleoli].

Authors:  N N Mamaev; T I Grichanova; D S Shandlorenko; A V Koloskov
Journal:  Gematol Transfuziol       Date:  1990-11       Impact factor: 0.172

8.  Erythropoiesis in myelodysplastic syndrome: expression of receptors for erythropoietin and kit ligand.

Authors:  B Backx; L Broeders; L H Hoefsloot; B Wognum; B Löwenberg
Journal:  Leukemia       Date:  1996-03       Impact factor: 11.528

9.  DNA content and cell cycle analysis of bone marrow cells in myelodysplastic syndromes (MDS).

Authors:  S W Peters; R E Clark; T G Hoy; A Jacobs
Journal:  Br J Haematol       Date:  1986-02       Impact factor: 6.998

10.  Proliferative activity of bone marrow cells in primary dysmyelopoietic (preleukemic) syndromes.

Authors:  C Montecucco; A Riccardi; E Traversi; P Giordano; G Mazzini; E Ascari
Journal:  Cancer       Date:  1983-10-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.